Press Releases

2025

• February 10, 2025

  IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress

2024

• October 16, 2024

  IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial “ACCELERATE Peanut” Evaluating IGNX001 in Peanut Allergy

• September 2, 2024

  IgGenix Presents Data Supporting Clinical Development of IGNX001 for Peanut Allergy at the 2024 ASCIA Annual Conference

• June 3, 2024

  IgGenix Demonstrates Potential of IGNX001 as a Targeted Therapeutic for Peanut Allergy at the 2024 EAACI Annual Meeting Ahead of Clinical Trial Launch

• February 22, 2024

  IgGenix Presents Groundbreaking Research Using its SEQ SIFTER™ Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual Meeting

2023

• November 14, 2023

  IgGenix Publishes New Data Supporting Further Development of Allergen-Specific Therapeutics for the Treatment of Peanut Allergy

• June 9, 2023

  IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy

• April 4, 2023

  IgGenix Announces Patent Granted by USPTO Covering the Generation of Allergen-Specific Antibodies

• March 1, 2023

  IgGenix Demonstrated Potential for Single-Cell RNA-Sequencing to Address Shellfish Allergies at the 2023 AAAAI Annual Meeting

• February 6, 2023

  IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy

2022

• August 19, 2022

  How Re-Engineering Antibodies Can Prevent Allergies (Labiotech.eu)

• July 1, 2022

  IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies

• April 26, 2022

  IgGenix Announces Move of Headquarters to Lilly Gateway Labs in South San Francisco

• February 23, 2022

  IgGenix Announces Presentation on Food Allergy Research at American Academy of Allergy, Asthma & Immunology Annual Meeting

2021

• July 27, 2021

  IgGenix Announces $25M in Series A1 Funding

• June 24, 2021

  IgGenix Announces Jessica Grossman, M.D., as Chief Executive Officer

2020

• November 6, 2020

  IgGenix: Antibody Engineering for Food Allergies (BioCentury)

• September 29, 2020

  IgGenix Congratulates Co-Founder Kari Nadeau, M.D., Ph.D., on Publication of Landmark Food Allergy Book

• August 4, 2020

  IgGenix Completes $10 Million Series A Financing

BACK